Limits...
Primary mediastinal large B-cell lymphoma: Clinical features, prognostic factors and survival with RCHOP in Arab patients in the PET scan era.

Al Shemmari S, Sankaranarayanan SP, Krishnan Y - Lung India (2014)

Bottom Line: Survival rates were compared using the log-rank test.A P < 0.05 was considered significant.The role of PET scan for response evaluation and the type of consolidation therapy needs to be further clarified.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, Sheikha Badriya Al Sabah Centre, Kuwait Cancer Control Center, Shuwaikh, Kuwait.

ABSTRACT

Objective: PMBCL is a distinct type of nonhodgkins lymphoma with specific clinicopathological features. To clarify clinical features, treatment alternatives and outcomes, we evaluated 28 Arab patients treated with chemotherapy or radiotherapy between 2006 and 2011.

Patients and methods: PMBCL lymphoma patients identified according to WHO classification and treated at KCCC between 2006 and 2011 were included in this study. Demographic and clinical data are presented as means or medians. Overall survival was estimated using the Kaplan-Meier method. Survival rates were compared using the log-rank test. A P < 0.05 was considered significant.

Results: The median age of the patients was 31 years and the male to female ratio was 2:1. Majority of the patients (75%) presented with stage I/II disease. Most had features of local extension like pleural effusion (18%) and SVCO (39%). Only 11% of the patients had bone marrow involvement at presentation. 96% of the patients required biopsy from the mediastinal mass either by image guided core biopsy (75%) or by surgical biopsy. Most patients were treated by RCHOP and involved field radiotherapy. Patients with positive PET scan after RCHOP chemotherapy received salvage chemotherapy and BEAM autologous marrow transplant. The five year OS for the entire group was 85% while the PFS was 73%. Patients who had PET scan for response evaluation had better OS [P = 0.013] and PFS [P = 0.039] when compared with those patients who received only radiotherapy based on CT scan evaluation.

Conclusion: PMBCL is a specific lymphoma entity seen in the young with good survival. The role of PET scan for response evaluation and the type of consolidation therapy needs to be further clarified.

No MeSH data available.


Related in: MedlinePlus

Overall survival (OS) for the entire group
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4129593&req=5

Figure 2: Overall survival (OS) for the entire group

Mentions: Three of the total 28 patients (10.7%) died in a median follow up of 40 months. The mean survival period was 69 months for the entire group with a 5-year overall survival of 85% [Figure 2]. We could not identify any prognostic factors for survival like sex, ECOG status or biochemical parameters. Bone marrow involvement at presentation was the only factor identified to predict response with a P value of 0.045. The 5 year EFS was 73% for the entire group [Figure 3].


Primary mediastinal large B-cell lymphoma: Clinical features, prognostic factors and survival with RCHOP in Arab patients in the PET scan era.

Al Shemmari S, Sankaranarayanan SP, Krishnan Y - Lung India (2014)

Overall survival (OS) for the entire group
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4129593&req=5

Figure 2: Overall survival (OS) for the entire group
Mentions: Three of the total 28 patients (10.7%) died in a median follow up of 40 months. The mean survival period was 69 months for the entire group with a 5-year overall survival of 85% [Figure 2]. We could not identify any prognostic factors for survival like sex, ECOG status or biochemical parameters. Bone marrow involvement at presentation was the only factor identified to predict response with a P value of 0.045. The 5 year EFS was 73% for the entire group [Figure 3].

Bottom Line: Survival rates were compared using the log-rank test.A P < 0.05 was considered significant.The role of PET scan for response evaluation and the type of consolidation therapy needs to be further clarified.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, Sheikha Badriya Al Sabah Centre, Kuwait Cancer Control Center, Shuwaikh, Kuwait.

ABSTRACT

Objective: PMBCL is a distinct type of nonhodgkins lymphoma with specific clinicopathological features. To clarify clinical features, treatment alternatives and outcomes, we evaluated 28 Arab patients treated with chemotherapy or radiotherapy between 2006 and 2011.

Patients and methods: PMBCL lymphoma patients identified according to WHO classification and treated at KCCC between 2006 and 2011 were included in this study. Demographic and clinical data are presented as means or medians. Overall survival was estimated using the Kaplan-Meier method. Survival rates were compared using the log-rank test. A P < 0.05 was considered significant.

Results: The median age of the patients was 31 years and the male to female ratio was 2:1. Majority of the patients (75%) presented with stage I/II disease. Most had features of local extension like pleural effusion (18%) and SVCO (39%). Only 11% of the patients had bone marrow involvement at presentation. 96% of the patients required biopsy from the mediastinal mass either by image guided core biopsy (75%) or by surgical biopsy. Most patients were treated by RCHOP and involved field radiotherapy. Patients with positive PET scan after RCHOP chemotherapy received salvage chemotherapy and BEAM autologous marrow transplant. The five year OS for the entire group was 85% while the PFS was 73%. Patients who had PET scan for response evaluation had better OS [P = 0.013] and PFS [P = 0.039] when compared with those patients who received only radiotherapy based on CT scan evaluation.

Conclusion: PMBCL is a specific lymphoma entity seen in the young with good survival. The role of PET scan for response evaluation and the type of consolidation therapy needs to be further clarified.

No MeSH data available.


Related in: MedlinePlus